Brainstorm Cell Therapeutics Appoints Executive Chairman; Chairman Resigns

What Happened

• Brainstorm Cell Therapeutics Inc. (BCLI) filed an 8-K reporting governance and leadership changes on July 24–26, 2026. The Board appointed director Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer effective July 24, 2026. Pitts received a stock option grant to purchase 900,000 shares; he will not receive base salary, cash bonus, or director compensation.
• Jacob Frenkel, Ph.D., resigned as Chairman and director on July 24, 2026 and moved into an advisory/consulting role under a Consulting Agreement. Frenkel received 100,000 restricted stock units (RSUs) and accelerated vesting and extended post-termination option exercise rights were approved in recognition of his service.
• On July 26, 2026, Ibrahim B. Dagher, MD, Executive VP and Chief Medical Officer, resigned and transitioned to a one-year consulting agreement that treats his consulting as “continued employment” for equity vesting purposes and provides vesting and extended exercise protections if he complies with the agreement.

Key Details

• Peter Pitts: granted option to buy 900,000 common shares (Stock Option Grant Notice dated July 24, 2026). Vesting: 25% on July 24, 2027, then remaining shares vest monthly over the next three years. No cash salary/bonus or director pay.
• Jacob Frenkel: resigned July 24, 2026; received 100,000 RSUs (50% vest on Oct 24, 2026; 50% on Apr 24, 2027). Board accelerated vesting of his outstanding options/RSUs and extended post-termination exercise period to the earlier of (a) the second anniversary of his resignation or (b) the option term expiration.
• Ibrahim Dagher: resigned July 26, 2026; entered one-year consulting agreement. While consulting, his service counts as continued employment for outstanding equity; if compliant at term end, all outstanding unvested awards will vest and post-termination exercise periods will be extended up to two years (or the option term limit).
• Company furnished a press release on July 28, 2026 announcing Pitts’s appointment and Frenkel’s resignation (Exhibit 99.1).

Why It Matters

• These are material governance and management changes: a new Executive Chairman (equity-compensated) and the former Chairman moving to an advisory role while the CMO transitions to consulting. Investors should note potential dilution from equity grants (900,000 options to Pitts and 100,000 RSUs to Frenkel) and changes in executive responsibilities.
• The agreements extend protections for departing executives’ equity (accelerated vesting and extended exercise windows), which can affect timing of share issuance and insider selling windows. The company disclosed these items in an 8-K and furnished a related press release for further details.